Use of a GLP-1glucagon-like peptide-1 receptor agonistwas first approved by the FDA in 2005 for patients with type-2 diabetes, but in 2014 also received FDA approval for obesity treatment
Most patients experience peak constipation during the first 24 weeks, with significant improvement by week 68 as your gut microbiome adapts
Yes, peptide therapy often complements hormone optimization programs beautifully, as both address fundamental aging mechanisms
Although the APAP toxicity-associated acute liver failure has better outcome than other causes of liver failure, mortality is still significant in 30% of cases without a liver transplant (for those who are deemed in need of a transplant)
13,14 The most common culprits for weight gain are antiepileptics, antihyperglycemics, antipsychotics, beta-blockers, and glucocorticoids
Q5: Is semaglutide FDA-approved